Evidence map›Paper›PMID 27661006›Full record

ReviewOncotarget2017

Type I insulin-like growth factor receptor signaling in hematological malignancies.

Deeksha Vishwamitra, Suraj Konnath George, Ping Shi, Ahmed O Kaseb, Hesham M Amin

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Deeksha VishwamitraDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Suraj Konnath GeorgeDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ping ShiState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China.
Ahmed O KasebDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hesham M AminDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · USEast China University of Science and Technology · CN

Funding

Role of IGF-IR tyrosine kinase in NPM-ALK-expressing T-cell lymphomaR01CA151533 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AMIN, HESHAM M · 2011 to 2015
$1.6M
Integrating plasma IGF-1 into novel classification of hepatocellular carcinomaR21CA170035 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KASEB, AHMED · 2012 to 2013
$366k
NCI NIH HHS R01 CA151533NCI NIH HHS R21 CA170035
6 · The paper itself

Abstract

The insulin-like growth factor (IGF) signaling system plays key roles in the establishment and progression of different types of cancer. In agreement with this idea, substantial evidence has shown that the type I IGF receptor (IGF-IR) and its primary ligand IGF-I are important for maintaining the survival of malignant cells of hematopoietic origin. In this review, we discuss current understanding of the role of IGF-IR signaling in cancer with a focus on the hematological neoplasms. We also address the emergence of IGF-IR as a potential therapeutic target for the treatment of different types of cancer including plasma cell myeloma, leukemia, and lymphoma.

Indexed as

ApoptosisCell AdhesionCell MovementCell ProliferationHumansInsulin-Like Growth Factor ILeukemiaLymphomaMultiple MyelomaReceptor, IGF Type 1Receptors, SomatomedinSignal TransductionIGF1 protein, humanIGF1R protein, humanInsulin-Like Growth Factor IReceptor, IGF Type 1Receptors, SomatomedinIGF-IRleukemialymphomaplasma cell myeloma

Identifiers

PMID27661006
PMCPMC5352101
OpenAlexW2497466108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.